论文部分内容阅读
肿瘤的免疫治疗作为恶性肿瘤综合治疗的重要组成部分,近年来受到了广泛的关注。树突状细胞(DC)是已知的功能最强的抗原呈递细胞,不仅能够激活自体的抗肿瘤免疫,同样能够提高异体免疫组织的抗肿瘤效应。为了探讨外周血来源的DC体外培养扩增和临床治疗的可行性和安全性,分析DC免疫治疗对于急性非淋巴细胞白血病自体骨髓移植患者长期生存的影响,利用CS3000Plus采集13例急性非淋巴细胞白血病自体骨髓移植后的病人的外周血单个核细胞,经过2周的体外培养后行DC免疫治疗,治疗后长期随访观察其无病生存时间。结果表明,无一例发现有与DC免疫治疗相关的严重不良反应;KaplanMeier生存分析结果为:DC组5年生存率为75.52%,非DC组5年生存率为45.71%,DC组在累计生存率上明显优于非DC组。结论:外周血来源的DC体外培养和临床治疗是安全可行的,急性非淋巴细胞白血病病人在自体骨髓移植术后应用DC免疫治疗延长了其无病生存时间,提高了长期生存率。
As an important part of the comprehensive treatment of malignant tumors, immunotherapy of tumors has drawn wide attention in recent years. Dendritic cells (DCs), the most potent antigen-presenting cells known, not only activate autologous antitumor immunity, but also enhance the anti-tumor effects of allogeneic immune tissues. In order to investigate the feasibility and safety of DC-derived DC in vitro culture and clinical treatment, the effect of DC immunotherapy on the long-term survival of patients with acute non-lymphocytic leukemia autologous bone marrow transplantation was analyzed. Thirteen cases of acute non-lymphocytic leukemia Peripheral blood mononuclear cells from patients with autologous bone marrow transplantation underwent DC immunotherapy after 2 weeks of in vitro culture. After treatment, their disease-free survival time was observed after long-term follow-up. The results of KaplanMeier survival analysis showed that the 5-year survival rate was 75.52% in DC group and 45.71% in non-DC group. The cumulative survival rate in DC group was significantly higher than that in DC group Obviously superior to non-DC group. CONCLUSION: Peripheral blood-derived DC in vitro culture and clinical treatment are safe and feasible. Acute non-lymphocytic leukemia patients using DC immunotherapy after autologous bone marrow transplantation prolong the disease-free survival time and improve the long-term survival rate.